Raymond James upgraded shares of Alpha Cognition (NASDAQ:ACOG - Free Report) to a moderate buy rating in a research note issued to investors on Tuesday,Zacks.com reports.
Separately, HC Wainwright began coverage on shares of Alpha Cognition in a research report on Tuesday, March 18th. They set a "buy" rating and a $20.00 target price for the company.
Read Our Latest Stock Report on Alpha Cognition
Alpha Cognition Trading Down 1.6 %
ACOG traded down $0.09 during trading on Tuesday, reaching $5.44. 4,217 shares of the company traded hands, compared to its average volume of 78,370. The stock has a market capitalization of $87.15 million, a P/E ratio of -2.13 and a beta of 2.50. The business's fifty day simple moving average is $5.85. Alpha Cognition has a 12-month low of $4.66 and a 12-month high of $7.00.
Alpha Cognition (NASDAQ:ACOG - Get Free Report) last issued its quarterly earnings results on Wednesday, April 2nd. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($1.50) by $0.99.
Institutional Investors Weigh In On Alpha Cognition
Institutional investors have recently added to or reduced their stakes in the stock. Rosalind Advisors Inc. purchased a new stake in Alpha Cognition during the 4th quarter valued at about $1,489,000. National Bank of Canada FI acquired a new position in shares of Alpha Cognition in the fourth quarter valued at approximately $69,000. Aristides Capital LLC purchased a new stake in shares of Alpha Cognition during the fourth quarter worth $1,178,000. ADAR1 Capital Management LLC acquired a new stake in Alpha Cognition in the fourth quarter valued at approximately $1,204,000. Finally, Altium Capital Management LLC acquired a new position in shares of Alpha Cognition during the fourth quarter worth $1,620,000.
Alpha Cognition Company Profile
(
Get Free Report)
Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Featured Stories
Before you consider Alpha Cognition, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Cognition wasn't on the list.
While Alpha Cognition currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
